This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Colorectal cancer	Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1; CD66a); hepatitis A virus cellular receptor 2 (HAVCR2; TIM3)	Cell culture and mouse studies suggest co-blockade of CEACAM1 and TIM3 could help enhance antitumor immunity to treat colorectal cancer. In a mouse model of colorectal cancer, antibody-mediated blockade of both CEACAM1 and TIM3 enhanced the antitumor immune response and delayed tumor growth compared with either antibody alone or a control antibody. Next steps include synthesizing checkpoint inhibitors that target the CEACAM1 and TIM3 pathways and testing the dual blockade in other cancer types.	Patent application filed; licensing status undisclosed	Huang, Y.-H. <i>et al. Nature</i> ; published online Oct. 26, 2014; doi:10.1038/nature13848 Contact: Richard S. Blumberg, Harvard Medical School, Boston, Mass. e-mail: rblumberg@partners.org
<i>SciBX</i> 7(45); doi:10.1038/scibx.2014.1315 Published online Nov. 20, 2014				